ReviewTropical diseases, travel medicine and vaccines2026
Traveling with chronic viral hepatitis.
Review in Tropical diseases, travel medicine and vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral hepatitis is one of the infectious diseases with an overall increasing mortality rate. The global burden of acute viral hepatitis remains substantial, with hepatitis A, B, C, D, and E responsible for millions of new cases annually and significant morbidity, especially in resource-limited settings and among travelers to endemic regions. People living with chronic viral hepatitis, especially with advanced liver disease, may face specific health risks and management challenges during travel, which makes preparing for travel especially important. Travel-related gastroenteritis or febrile syndromes can lead to more severe clinical outcomes due to limited hepatic reserve. Newly acquired hepatitis A and E significantly increase the risk of liver failure and mortality in patients with chronic liver disease. This review emphasizes the critical importance of checking the immunization status of patients with chronic viral hepatitis before travel, managing antiviral medications, assessing risk of complications, evaluating the health infrastructure of the destination country, and applying food and water safety precautions. Safe travel for patients with chronic viral hepatitis can be facilitated through an appropriate risk assessment and a personalized travel plan.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.